Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway

Fig. 3

Administration of exogenous IL-1β in vivo aggravated the severity of EAMG rats treated with Ac-YVAD-cmk. The rats treated with Ac-YVAD-cmk showed lower clinical scores from day 30 to 43 p.i. compared with rats in Ac-YVAD-cmk with IL-1β group (# p < 0.05) and EAMG group (*p < 0.05) (a). Anti-R97-116 peptide IgG titers and the affinity index of anti-R97-116 peptide IgG were determined by ELISA, and results were determined by OD values at 450 nm subtracted from 630 nm (b). Anti-R97-116 peptide IgG1, IgG2a, and IgG2b titers were determined by ELISA, and results were determined by OD values at 450 nm subtracted from 630 nm (c). Serum was obtained on day 43 p.i. All results are expressed as means ± SD (n = 6 in each group) (*p < 0.05, **p < 0.01, and ***p < 0.001)

Back to article page